Evidence map›Paper›PMID 27540002›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2016

Beneficial Effect of the Nitric Oxide Donor Compound 3-(1,3-Dioxoisoindolin-2-yl)Benzyl Nitrate on Dysregulated Phosphodiesterase 5, NADPH Oxidase, and Nitrosative Stress in the Sickle Cell Mouse Penis: Implication for Priapism Treatment.

Fábio H Silva, Serkan Karakus, Biljana Musicki, Hotaka Matsui, Trinity J Bivalacqua, Jean L Dos Santos, Fernando F Costa, Arthur L Burnett

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Fábio H SilvaJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland (F.H.S., S.K., B.M., H.M., T.J.B., A.L.B.); Hematology and Hemotherapy Center, University of Campinas, Campinas, SP, Brazil (F.H.S., F.F.C.); and Laboratório de Pesquisa e Desenvolvimento de Fármacos, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, Araraquara, SP, Brazil (J.L.S.) fabiohsilva87@gmail.com.
Serkan KarakusJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland (F.H.S., S.K., B.M., H.M., T.J.B., A.L.B.); Hematology and Hemotherapy Center, University of Campinas, Campinas, SP, Brazil (F.H.S., F.F.C.); and Laboratório de Pesquisa e Desenvolvimento de Fármacos, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, Araraquara, SP, Brazil (J.L.S.).
Biljana MusickiJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland (F.H.S., S.K., B.M., H.M., T.J.B., A.L.B.); Hematology and Hemotherapy Center, University of Campinas, Campinas, SP, Brazil (F.H.S., F.F.C.); and Laboratório de Pesquisa e Desenvolvimento de Fármacos, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, Araraquara, SP, Brazil (J.L.S.).
Hotaka MatsuiJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland (F.H.S., S.K., B.M., H.M., T.J.B., A.L.B.); Hematology and Hemotherapy Center, University of Campinas, Campinas, SP, Brazil (F.H.S., F.F.C.); and Laboratório de Pesquisa e Desenvolvimento de Fármacos, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, Araraquara, SP, Brazil (J.L.S.).
Trinity J BivalacquaJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland (F.H.S., S.K., B.M., H.M., T.J.B., A.L.B.); Hematology and Hemotherapy Center, University of Campinas, Campinas, SP, Brazil (F.H.S., F.F.C.); and Laboratório de Pesquisa e Desenvolvimento de Fármacos, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, Araraquara, SP, Brazil (J.L.S.).
Jean L Dos SantosJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland (F.H.S., S.K., B.M., H.M., T.J.B., A.L.B.); Hematology and Hemotherapy Center, University of Campinas, Campinas, SP, Brazil (F.H.S., F.F.C.); and Laboratório de Pesquisa e Desenvolvimento de Fármacos, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, Araraquara, SP, Brazil (J.L.S.).
Fernando F CostaJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland (F.H.S., S.K., B.M., H.M., T.J.B., A.L.B.); Hematology and Hemotherapy Center, University of Campinas, Campinas, SP, Brazil (F.H.S., F.F.C.); and Laboratório de Pesquisa e Desenvolvimento de Fármacos, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, Araraquara, SP, Brazil (J.L.S.).
Arthur L BurnettJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland (F.H.S., S.K., B.M., H.M., T.J.B., A.L.B.); Hematology and Hemotherapy Center, University of Campinas, Campinas, SP, Brazil (F.H.S., F.F.C.); and Laboratório de Pesquisa e Desenvolvimento de Fármacos, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista, Araraquara, SP, Brazil (J.L.S.).
Johns Hopkins University · USInstituto de Ciências Farmacêuticas · BRUniversidade Estadual Paulista (Unesp) · BR

Funding

NOS Regulation in the PenisR01DK067223 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI BURNETT, ARTHUR LOUIS · 2005 to 2015
$3.5M
NIDDK NIH HHS R01 DK067223
6 · The paper itself

Abstract

Patients with sickle cell disease (SCD) display priapism, and dysregulated nitric oxide (NO) pathway may contribute to this condition. However, current therapies offered for the prevention of priapism in SCD are few. The 3-(1,3-dioxoisoindolin-2-yl)benzyl nitrate (compound 4C) was synthesized through molecular hybridization of hydroxyurea and thalidomide, which displays an NO-donor property. This study aimed to evaluate the effects of compound 4C on functional and molecular alterations of erectile function in murine models that display low NO bioavailability, SCD transgenic mice, and endothelial NO synthase and neuronal NO synthase double gene-deficient (dNOS

Indexed as

AcetylcholineAnemia, Sickle CellAnimalsCell Adhesion MoleculesCyclic Nucleotide Phosphodiesterases, Type 5Dose-Response Relationship, DrugElectric StimulationGene Expression Regulation, EnzymologicHumansIsoindolesMaleMembrane GlycoproteinsMiceMicrofilament ProteinsNADPH Oxidase 2NADPH Oxidases3-(1,3-dioxoisoindolin-2-yl)benzyl nitrate3-nitrotyrosineAcetylcholineCell Adhesion MoleculesCybb protein, mouseCyclic Nucleotide Phosphodiesterases, Type 5IsoindolesMembrane GlycoproteinsMicrofilament ProteinsNADPH Oxidase 2NADPH OxidasesNitratesNitric Oxide DonorsNitroprussidePhosphoproteinsPhthalimidesReactive Nitrogen SpeciesTyrosineVasodilator-Stimulated Phosphoprotein

Identifiers

PMID27540002
PMCPMC5074485
OpenAlexW2517249938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.